Comparison of Two Different Regimens of Combined Interferon-α2A and Lamivudine Therapy in Children with Chronic Hepatitis B Infection

Abstract

Simultaneous 3TC+IFN-alpha2a yields a higher response and earlier antiHBe seroconversion and viral clearance than consecutive combined therapy. Relapse rate is low. Predictors of response are high basal ALT and high HAI scores. 3TC can be administered for 24 months without any side effect and breakthrough rate is comparable with previous studies.